← Leaderboards
Alan F List
University Of Arizona
$3,514,642
Attributed
$3,514,642
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $466.7K · FY2008–12$500K$375K$250K$125K$0
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$3,514,642 · 4
By mechanism
R01$2,195,745 · 1
K12$749,445 · 1
U54$296,752 · 1
R21$272,700 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Arizona
Same institution · by research overlap
- Donata Vercelli$11,141,049
- Howard Ochman$7,906,557
- Murray H Brilliant$3,685,650
Others in their field
Top investigators on “Thalidomide”
- Walter John Curran · Thomas Jefferson University$26,641,549
- William G Kaelin · Dana-Farber Cancer Institute$9,761,992
- Patricia M Rodier · University Of Rochester$5,610,286
- Michele Pagano · New York University School Of Medicine$5,565,349
- Keith R. McCrae · Case Western Reserve University$5,447,978
- Peter Leif Bergsagel · Weill Medical College Of Cornell Univ$5,124,352
Research focus
ThalidomideDarbepoetin AlfaBiologyCytotoxicityAging5q31AccountingAdverse EffectsCombined Modality TherapyCytogeneticsAttenuatedBaseBiologicalAmericanClinical ResearchAnalogCc-5013Cell Cycle ArrestAffectCellsChemosensitizationApoptosisChromosomesDensity
Grant awards (10)
Phosphatase Targets of Lenalidomide in Myelodysplastic Syndrome$424,232
R01 · FY2012 · CA · contact PI
Phosphatase Targets of Lenalidomide in Myelodysplastic Syndrome$426,554
R01 · FY2011 · CA · contact PI
Phosphatase Targets of Lenalidomide in Myelodysplastic Syndrome$442,211
R01 · FY2010 · CA · contact PI
Phosphatase Targets of Lenalidomide in Myelodysplastic Syndrome$436,029
R01 · FY2009 · CA · contact PI
Phosphatase Targets of Lenalidomide in Myelodysplastic Syndrome$466,719
R01 · FY2008 · CA · contact PI
CLINICAL SCHOLARS IN ONCOLOGY$749,445
K12 · FY2004 · CA
Targeted inhibition of angiogenesis in myelodysplastic s$296,752
U54 · FY2002 · CA
RELEVANCE OF THE IL 1B TRANSLOCATOR ABC 1 IN AML$136,350
R21 · FY2001 · CA
Targeted inhibition of angiogenesis in myelodysplastic s$0
U54 · FY2001 · CA
RELEVANCE OF THE IL 1B TRANSLOCATOR ABC 1 IN AML$136,350
R21 · FY2000 · CA